» Articles » PMID: 25654611

Vaccination Coverage Among Adults, Excluding Influenza Vaccination - United States, 2013

Overview
Date 2015 Feb 6
PMID 25654611
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinations are recommended throughout life to prevent vaccine-preventable diseases and their sequelae. Adult vaccination coverage, however, remains low for most routinely recommended vaccines and below Healthy People 2020 targets. In October 2014, the Advisory Committee on Immunization Practices (ACIP) approved the adult immunization schedule for 2015. With the exception of influenza vaccination, which is recommended for all adults each year, other adult vaccinations are recommended for specific populations based on a person's age, health conditions, behavioral risk factors (e.g., injection drug use), occupation, travel, and other indications. To assess vaccination coverage among adults aged ≥19 years for selected vaccines, CDC analyzed data from the 2013 National Health Interview Survey (NHIS). This report highlights results of that analysis for pneumococcal, tetanus toxoid-containing (tetanus and diphtheria vaccine [Td] or tetanus and diphtheria with acellular pertussis vaccine [Tdap]), hepatitis A, hepatitis B, herpes zoster (shingles), and human papillomavirus (HPV) vaccines by selected characteristics (age, race/ethnicity,† and vaccination indication). Influenza vaccination coverage estimates for the 2013-14 influenza season have been published separately. Compared with 2012, only modest increases occurred in Tdap vaccination among adults aged ≥19 years (a 2.9 percentage point increase to 17.2%), herpes zoster vaccination among adults aged ≥60 years (a 4.1 percentage point increase to 24.2%), and HPV vaccination among males aged 19-26 years (a 3.6 percentage point increase to 5.9%); coverage among adults in the United States for the other vaccines did not improve. Racial/ethnic disparities in coverage persisted for all six vaccines and widened for Tdap and herpes zoster vaccination. Increases in vaccination coverage are needed to reduce the occurrence of vaccine-preventable diseases among adults. Awareness of the need for vaccines for adults is low among the general population, and adult patients largely rely on health care provider recommendations for vaccination. The Community Preventive Services Task Force and the National Vaccine Advisory Committee have recommended that health care providers incorporate vaccination needs assessment, recommendation, and offer of vaccination into every clinical encounter with adult patients to improve vaccination rates and to narrow the widening racial/ethnic disparities in vaccination coverage.

Citing Articles

Predictors of COVID-19 vaccine uptake among people who use substances: a case study in Tehran.

Karimi S, Amadi S, Rampisheh Z, Tayefi B, SoleimanvandiAzar N, Higgs P Subst Abuse Treat Prev Policy. 2024; 19(1):15.

PMID: 38409120 PMC: 10895917. DOI: 10.1186/s13011-024-00596-9.


Development of a cervical cancer prevention text-messaging program for women living with HIV.

Ciceron A, Berg C, Clausen M, Jeon M, Abroms L, Le D Health Educ Res. 2023; 38(6):587-596.

PMID: 37436827 PMC: 11491630. DOI: 10.1093/her/cyad024.


Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia.

Al-Orini D, Alshoshan A, Almutiri A, Almreef A, Alrashidi E, Almutiq A Vaccines (Basel). 2023; 11(3).

PMID: 36992235 PMC: 10059133. DOI: 10.3390/vaccines11030651.


The Effect of the COVID-19 Pandemic on Vaccination Behaviour of Individuals over the Age of 65 Years in Turkey: Single-Centre Experience.

Ergin A, Karagoz Ozen D, Demirag M Vaccines (Basel). 2023; 11(1).

PMID: 36679879 PMC: 9862139. DOI: 10.3390/vaccines11010034.


Activation of Interferon-Stimulated Genes following Varicella-Zoster Virus Infection in a Human iPSC-Derived Neuronal In Vitro Model Depends on Exogenous Interferon-α.

Boeren M, Van Breedam E, Buyle-Huybrecht T, Lebrun M, Meysman P, Sadzot-Delvaux C Viruses. 2022; 14(11).

PMID: 36423126 PMC: 9693540. DOI: 10.3390/v14112517.


References
1.
Rolnick S, Parker E, Nordin J, Hedblom B, Wei F, Kerby T . Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?. Vaccine. 2013; 31(37):3928-35. PMC: 4689428. DOI: 10.1016/j.vaccine.2013.06.041. View

2.
Elam-Evans L, Yankey D, Jeyarajah J, Singleton J, Curtis R, MacNeil J . National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(29):625-33. PMC: 5779424. View

3.
Burger E, Sy S, Nygard M, Kristiansen I, Kim J . Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway. J Infect Dis. 2014; 211(2):206-15. PMC: 4342693. DOI: 10.1093/infdis/jiu413. View

4.
Chesson H, Markowitz L . The cost-effectiveness of human papillomavirus vaccine catch-up programs for women. J Infect Dis. 2014; 211(2):172-4. PMC: 6745691. DOI: 10.1093/infdis/jiu414. View

5.
Kim D, Bridges C, Harriman K . Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016. Ann Intern Med. 2016; 164(3):184-94. DOI: 10.7326/M15-3005. View